Celldex Therapeutics, Inc.
CLDX
$15.94
-$0.47-2.86%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.18M | 3.19M | 2.50M | 156.00K | 4.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.18M | 3.19M | 2.50M | 156.00K | 4.13M |
| Cost of Revenue | 46.94M | 45.26M | 3.88M | 31.66M | 30.43M |
| Gross Profit | -45.76M | -42.07M | -1.39M | -31.51M | -26.30M |
| SG&A Expenses | 10.26M | 10.05M | 9.13M | 9.10M | 8.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.20M | 55.32M | 48.82M | 40.76M | 39.26M |
| Operating Income | -56.03M | -52.13M | -46.32M | -40.61M | -35.13M |
| Income Before Tax | -47.09M | -42.12M | -35.84M | -32.81M | -43.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.09M | -42.12M | -35.84M | -32.81M | -43.31M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.09M | -42.12M | -35.84M | -32.81M | -43.31M |
| EBIT | -56.03M | -52.13M | -46.32M | -40.61M | -35.13M |
| EBITDA | -55.21M | -51.34M | -45.52M | -39.83M | -34.37M |
| EPS Basic | -0.71 | -0.64 | -0.54 | -0.56 | -0.83 |
| Normalized Basic EPS | -0.44 | -0.40 | -0.34 | -0.35 | -0.37 |
| EPS Diluted | -0.71 | -0.64 | -0.54 | -0.56 | -0.83 |
| Normalized Diluted EPS | -0.44 | -0.40 | -0.34 | -0.35 | -0.37 |
| Average Basic Shares Outstanding | 66.35M | 66.29M | 66.02M | 58.87M | 52.03M |
| Average Diluted Shares Outstanding | 66.35M | 66.29M | 66.02M | 58.87M | 52.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
